Currently, there is an increased use of monoclonal antibodies in the context of the treatment of patients that suffer from cancer. In cooperation with a leading, internationally operating pharma company, this research group in Linz investigates the function of these innovative therapeutics on a molecular level.

In contrast to other running projects of the TIMed Center, the Biophysical Characterization of Therapeutic Antibodies is a privately funded contract work. 

• Head: DI Dr. Johannes Preiner
• Funding Program: none (contract project)
• Duration: since 09/2017
• Extended: since 08/2020
• Faculty: Linz